Boston Scientific Corporation (LON:0HOY)
105.18
-0.38 (-0.36%)
At close: Aug 1, 2025
Accolade Revenue
Boston Scientific had revenue of $5.06B USD in the quarter ending June 30, 2025, with 22.84% growth. This brings the company's revenue in the last twelve months to $18.49B, up 21.44% year-over-year. In the year 2024, Boston Scientific had annual revenue of $16.75B with 17.61% growth.
Revenue (ttm)
$18.49B
Revenue Growth
+21.44%
P/S Ratio
8.74
Revenue / Employee
$348.94K
Employees
53,000
Market Cap
117.92B
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Boston Scientific News
- 2 days ago - 10 stocks favored to gain up to 30% in a sector that has missed this year's rally - Market Watch
- 9 days ago - This health care stock forming a 'big base breakout' is ready to separate from the pack, charts indicate - CNBC
- 10 days ago - Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance - Benzinga
- 10 days ago - Cramer's Stop Trading: Boston Scientific - CNBC
- 10 days ago - Boston Scientific Eyes Breakout On Strong Second Quarter, Guidance - Investor's Business Daily
- 10 days ago - Boston Scientific lifts annual profit view on steady heart devices demand - Reuters
- 10 days ago - Boston Scientific Non-GAAP EPS of $0.75 beats by $0.02, revenue of $5.06B beats by $170M - Seeking Alpha